Study of Aerosolized Peginterferon Alfa-2b to Treat Respiratory Syncytial Virus Pneumonia in Children Aged 1 to 3 Years

What this Trial Is About

Researchers are evaluating the safety and effectiveness of aerosolized Peginterferon alpha-2b injection for treating children aged 1 to 3 years with respiratory syncytial virus RSV pneumonia. This multicenter, randomized, open-label, parallel-controlled clinical study aims to compare two doses of Peginterferon alpha-2b with standard care to better understand its potential benefits in this young population. Participants will be randomly assigned to one of three groups a 45 mcg dose Peginterferon alpha-2b group, a 90 mcg dose Peginterferon alpha-2b group, or a control group receiving only symptomatic and supportive treatment. The medication is given by nebulization on the 1st, 3rd, and 5th days. The study includes a screening period, a treatment period, and a follow-up period to monitor participants progress and response. During the study, children will be closely monitored for improvement in major clinical symptoms like fever, cough, and wheezing, as well as physical signs such as rapid breathing and lung sounds. The main outcomes measured include the time until these symptoms and signs disappear, assessed by day 6. Researchers will also compare treatment efficacy rates, symptom relief at days 3 and 5, and total hospitalization duration among groups. Safety and response will be regularly evaluated throughout the study and follow-up phases.

Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia